Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.36 |
| ▸ | LGALS9 | O00182 | 2/20 | 0.35 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.35 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.35 |
| ▸ | LGALS7; LGALS7B | P47929 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | FGF1 | P05230 | 1/20 | 0.33 |
| ▸ | FGF2 | P09038 | 1/20 | 0.33 |
| ▸ | VEGFA | P15692 | 1/20 | 0.33 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25496003 | 0.94 | PDE4B (0.33) | TMPRSS2 | |
| SCHEMBL25495999 | 0.89 | TMPRSS2 (0.32) | TMPRSS2 | |
| SCHEMBL19101768 | 0.88 | TMPRSS2 (0.42) | TMPRSS2LGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| SCHEMBL25495783 | 0.85 | ADORA3 (0.42) | LGALS9LGALS1LGALS3LGALS7; LGALS7BADORA3 | |
| SCHEMBL25495987 | 0.85 | TMPRSS2 (0.41) | TMPRSS2LGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| SCHEMBL25496000 | 0.84 | PDE4B (0.31) | — | |
| SCHEMBL19101885 | 0.81 | TMPRSS2 (0.37) | TMPRSS2 | |
| SCHEMBL16708478 | 0.80 | TMPRSS2 (0.39) | TMPRSS2ADORA3 | |
| SCHEMBL25495889 | 0.79 | LGALS9 (0.35) | LGALS9LGALS1LGALS3LGALS7; LGALS7BADORA1 | |
| SCHEMBL25495781 | 0.79 | ADORA3 (0.42) | ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146410-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146410-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, MAVS | TMPRSS2 3340/4885LGALS9 3752/4885LGALS1 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.